Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615933 | 0.94 | QDPR (0.43) | PTGS2RARARARBRARGNR1H4 | |
| SCHEMBL4295886 | 0.83 | RARA (0.42) | PTGS2RARARARBRARGCYP19A1 | |
| SCHEMBL2070644 | 0.83 | ESR2 (0.39) | PTGS2NR1H4ESR1ESR2TP53 | |
| SCHEMBL2069685 | 0.81 | RARA (0.42) | PTGS2RARARARBRARGCYP19A1 | |
| SCHEMBL616469 | 0.80 | ESR1 (0.43) | RARARARBRARGNR1H4QDPR | |
| SCHEMBL615914 | 0.78 | HSD17B1 (0.41) | PTGS2RARARARGNR1H4ESR1 | |
| SCHEMBL616710 | 0.78 | RARA (0.49) | PTGS2RARARARBRARGCYP19A1 | |
| SCHEMBL616661 | 0.77 | ESR1 (0.43) | RARARARBRARGNR1H4ESR1 | |
| SCHEMBL612956 | 0.74 | MAOB (0.49) | PTGS2RARARARBRARGNR1H4 | |
| SCHEMBL616913 | 0.71 | ALOX15 (0.46) | PTGS2NR1H4ESR2TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367659-B2 | Oxazinyl isoflavonoid compounds, medicaments and use | MARSHALL EDWARDS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | MARSHALL EDWARDS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2125831-B1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RES PTY LTD (AU) | 2011-12-28 | — | — | EP | disclosed |
| EP-2334296-A1 | IMMUNOMODULATING ACTIVITIES | Novogen Research Pty. Ltd. (AU) | 2011-06-22 | — | — | EP | disclosed |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2011-02-24 | — | — | US | disclosed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | disclosed |
| EP-2125831-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | Novogen Research Pty. Ltd. (AU) | 2009-12-02 | — | — | EP | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| WO-2008106715-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | CD4, NFATC1, HRH2 | PTGS2 692/4885RARA 743/4885RARB 818/4885 |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | TNNI3, NFE2L2, OAT | PTGS2 25/4885RARA 4617/4885RARB 4581/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | PTGS2 440/4885RARA 2668/4885RARB 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.